Member Info for EmeraldCarrots

In which case once the buys have eaten through it the sp should take off!

Here's hoping!!

Know what will. As I posted yesterday:-

I have concluded that is it the HER2 assay test being developed with Bioview for BREAST Cancer that is likely to be the best World wide money spinner for Angle. This HER2 protein test can ONLY be done with LIVE cancer cells as I understand it. Angle's Parsortix machine is the only machine in the World that can relativerly easily separate a single LIVE cancerous circulating Breast cancer cell for the Bioview test from a standard blood sample. Clearly the Directors of Bioview realised the potential here and that is why they have invested over £1m. Both Companies have FDA approval for their machines use in the USA.

I belive ON ITS OWN this service, world wide could generate massive profits for both Companies. You send the blood sample to them and they tell you the current HER2 status deternining if the current treatment should be changed or not. Simple as that it seems to me.

It's only a matter of time before the information LIVE circulating cancerous cells can give us about a persons cancer helps determine the best treatments IMHO.

Just scratching the surface. We simply don't know (yet) what other information the proteins and RNA can give us from the LIVE circulation cancer cells.

All IMHO.

1 sell recommendation with the sp falling from over 80p to 43p??

Makes no sense to me.

Must be Israel/Gaza linked all I can think.

Once dust settles back up one presumes. Could be a big oppertunity.

All IMHO.

Found this.

"The 11 analysts offering 12 month price targets for Petrofac Ltd have a median target of 85.08, with a high estimate of 105.53 and a low estimate of 35.18. The median estimate represents a 89.82% increase from the last price of 44.82."

https://markets.ft.com/data/equities/tearsheet/forecasts?s=PFC:LSE

Hello.

03-Jul-23 Jefferies Hold - 80.00 Reiteration

19-May-23 Barclays Equal Weight - 200.00 Reiteration

12-Apr-23 Berenberg Bank Buy - 110.00 Reiteration

18-Jan-23 Barclays Equal Weight 200.00 200.00 Reiteration

80+200+110+200=590 / 4 = 147p.

The CURRENT sp is 44p.....

03-Jul-23 Jefferies Hold - 80.00 Reiteration

19-May-23 Barclays Equal Weight - 200.00 Reiteration

12-Apr-23 Berenberg Bank Buy - 110.00 Reiteration

18-Jan-23 Barclays Equal Weight 200.00 200.00 Reiteration

80+200+110+200=590 / 4 = 147p.

The currect sp is 44p.....

Https://www.fitchratings.com/research/corporate-finance/fitch-revises-petrofac-outlook-to-stable-affirms-idr-at-b-27-09-2023

Having had another look at Angle Plc's prospects it's obvious that in time they will generate significant revenues.

Again I have concluded that is it the HER2 assay test being developed with Bioview for BREAST Cancer that is likely to be the best World wide money spinner for Angle. This HER2 protein test can ONLY be done with LIVE cancer cells as I understand it. Angle's Parsortix machine is the only machine in the World that can relativerly easily separate a single LIVE cancerous circulating Breast cancer cell for the Bioview test. Clearly the Directors of Bioview realised the potential here and that is why they have invested over £1m. Both Companies have FDA approval for their machines use in the USA.

I belive ON ITS OWN this service, world wide could generate massive profits for both Companies. You send the blood sample to them and they tell you the current HER2 status deternining if the current treatment should be changed or not. Simple as that it seems to me.

It's only a matter of time before the information LIVE circulating cancerous cells can give us about a persons cancer helps determine the best treatments IMHO.

Just scratching the surface. We simply don't know (yet) what other information the proteins and RNA can give us from the LIVE circulation cancer cells.

All IMHO.

This test is targeing a major market opportunity for Angle.

I found this on the WWW:-

"A PD-L1 test measures what percentage of cells in a tumor “express” PD-L1. Tumors that express high amounts of PD-L1 (50% or greater) may respond particularly well to checkpoint inhibitors (a type of immunotherapy drug).".

Also this:-

"Programmed death-ligand 1 (PD-L1) is the primary ligand of PD-1 and is constitutively expressed on antigen presenting cells, mesenchymal stem cells and bone marrow-derived mast cells. In addition, PD-L1 is also expressed on a wide range of tumor cells, including lung cancer, breast cancer and melanoma.".

As I understand it the test will enable highly accurate, repeatable, and precise results for CTC PD-L1 biomarker expression during cancer therapy studies. This should give studies quicker more accurate information about the treatment response. Then would give them the opportunity to adjust future treatments to make them more effective.

See here:-

https://angleplc.com/onc-adapt-laboratories/portrait-pd-l1/

All IMHO.

Developing the HER2 assay test with Bioview AS SOON AS POSSIBLE.

I would give it ****TOP PRIORITY****.

All IMHO.

Up over the pond!

Up 15.2%.

Between 350 and 450 million Euros to ........... wait for it..............350 and 400 million Euros.

Can me mad but the bottom figure seems the same.......... 350 million!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

I thought the sp drop testerday was ludicrous, with a capital "L".

- It's even down a bit today ...... down 2.3%.

Mad.

All IMHO.

Up 12% now.

Up 10% suddenly.

. You manage both and should be banned from this site IMHO.

The sp has gone from over 80p to 46p, yet there has been no change in the holdings of the major shareholders?

I find that totally amazing. The last TR-1 RNS I can see is dated 28/11/2022!! Possible I suppose, but highly surprising.

Note "TR-1: - Standard form for notification of major holdings".

All IMHO.

Up more - now 4%!

Up *** 3.7% now ***